AstraZeneca’s cardiovascular-friendly drug, Axanum, has been approved for use in 23 EU countries and Norway.
The once-daily medicine is a combination of low-dose ASA (aspirin) and esomeprazole, indicated for prevention of cardiovascular (CV) events in high-risk patients who are likely to develop gastric ulcers.
Tony Zook, Executive Vice President of AstraZeneca’s Global Commercial Organisation says the company is pleased the drug has joined the “significant regulatory approvals” the company has had recently.
Unlike generic aspirin medicines, Axanum can protect patients against gastric ulcers. Esomeprazole is an active ingredient which reduces the risk of peptic ulcer development and is the only proton pump inhibitor (PPI) approved to reduce the risk of re-bleeding in peptic ulcer bleed patients.
AstraZeneca is a global biopharmaceutical company which develops and commercialises prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious diseases.